Fulcrum Therapeutics (FULC) Interest Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Interest Expenses data on file, last reported at $27.1 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 202.27% year-over-year to $27.1 million in Q1 2026; TTM through Mar 2026 was $27.1 million, a 202.27% increase from a year earlier, with the FY2025 full-year figure at $76.5 million, up 47.83% from the prior year.
• Interest Expenses for Q1 2026 stood at $27.1 million, down from $61.4 million in the prior quarter.
• Over the last five years, Interest Expenses for FULC reached as high as $164.5 million in Q4 2022 and fell as low as $1.2 million in Q2 2022.
• Historically, Interest Expenses has averaged $31.3 million across 5 years, with a median of $15.1 million in 2023.
• Across the five-year window, Interest Expenses slumped 96.39% in 2022 and jumped 3239.76% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $164.5 million in 2022, then sank by 90.81% to $15.1 million in 2023, then jumped by 242.42% to $51.8 million in 2024, then gained by 18.62% to $61.4 million in 2025, then tumbled by 55.87% to $27.1 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $27.1 million in Q1 2026, $61.4 million in Q4 2025, and $43.3 million in Q3 2025.